SUPPRELIN: payments to doctors
Payments that named SUPPRELIN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $142K
- Providers
- 496
- Transactions
- 1,341
- Average per transaction
- $106
The per-transaction average — $106 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 496 providers the average total is $287, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Endo Pharmaceuticals Inc. | $124,307 | 87.2% |
| Endo USA, Inc. | $18,169 | 12.8% |